Jefferies initiated coverage of Crescent Biopharma (CBIO) with a Buy rating and $26 price target Crescent is a preclinical-stage oncology company with CR-001 as its lead asset, the analyst tells investors in a research note. Jefferies believes in the PD-(L)1xVEGF class and sees an “intriguing” risk/reward at current share levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBIO: